Alpha-adrenoceptor antagonists in neurogenic lower urinary tract dysfunction

Urology

Volumn 53, Issue 3 SUPPL. A, 1999, Pages 21-28

  Sullivan, Jonathan ^a   Abrams, Paul ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; INDORAMIN; PHENOXYBENZAMINE; PHENTOLAMINE; PRAZOSIN; TAMSULOSIN; TERAZOSIN; URAPIDIL;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ARTICLE; AUTONOMIC HYPERREFLEXIA; BLADDER CAPACITY; CLINICAL TRIAL; HUMAN; NEUROGENIC BLADDER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; URINARY TRACT DISEASE;

EID: 0033062338     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00535-4     Document Type: Article

References (53)

1. Schurch B., Yasuda K., Rossier A.B. Detrusor bladder neck dyssynergia revisited. J Urol. 152:1994;2066-2070.
2. Blaivas J.G., Sinha I.R., Zayed A.A.H., Labib K.B. Detrusor-external sphincter dyssynergia. J Urol. 125:1981;542-544.
3. Seltzman A.A. Urologic complications of spinal cord injury. Urol Clin North Am. 20:1993;453-464.
4. McGuire E.J., Savastano J.A. Long-term follow-up of spinal cord injury patients managed by intermittent catheterization. J Urol. 129:1983;775-776.
5. Watanabe T., Rivas D.A., Chancellor M.B. Urodynamics of spinal cord injury. Urol Clin North Am. 23:1996;373-384.
6. Turner W.H., Harrison S.C.W. Progress in the rehabilitation of neuropathic bladders - what can we do today? Curr Opin Urol. 7:1997;146-154.
7. McGuire E.J., Woodside J.R., Borden T.A. Upper urinary tract deterioration in patients with myelodysplasia and detrusor hypertonia a follow-up study . J Urol. 129:1983;823-826.
8. Harris F.L., Cundiff G.W., Theofrastous J.P., et al. Bladder compliance in neurologically intact women. Neurourol Urodyn. 15:1996;483-488.
9. Wein AJ: Neuromuscular dysfunction of the lower urinary tract and its treatment. Chapter 29. in, Walsh PC, Retik AB, Vaughan ED, et al. (Eds). Campbell's Urology (7th ed). Philadelphia, WB Saunders, 1998, pp 953-1006.
10. Sotolongo JR Jr: Causes and treatment of neurogenic bladder dysfunction. Chapter 38. in, Krane PJ, Siroky MB, and Fitzpatrick JM (Eds). Clinical Urology. Philadelphia, JB Lippincott, 1994, pp 558-68.
11. Kotkin L., Milam D.F. Evaluation and management of the urologic consequences of neurologic disease. Techniques Urol. 2:1997;210-219.
12. Kramer G., Stöhrer M. Neurourology. Curr Opin Urol. 6:1996;176-183.
13. Sundin T., Dahlström A., Norlén L., et al. The sympathetic innervation and adrenoceptor function of the human lower urinary tract in the normal state and after parasympathetic denervation. Invest Urol. 14:1977;322-328.
14. Perlberg S., Caine M. Adrenergic response of bladder muscle in prostatic obstruction. Urology. 20:1982;524-527.
15. Chapple CR: The role of neural factors in prostatic obstruction and the pathogenesis of secondary detrusor instability. University of London, MD Thesis, 1990.
16. Restorick J.M., Mundy A.R. The density of cholinergic and alpha and beta receptors in the normal and hyper-reflexic human detrusor. Br J Urol. 63:1989;32-35.
17. McGuire E.J., Savastano J.A. Effect of alpha-adrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol Urodyn. 4:1985;139-142.
18. Skehan A.M., Downie J.W., Awad S.A. Control of detrusor stiffness in the chronic decentralized feline bladder. J Urol. 149:1993;1165-1173.
19. Lepor H., Theune C. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms. J Urol. 154:1995;116-118.
20. Gleason D.M., Bottacini M.R. Effect of terazosin on urine storage in the aging male with prostatism. Neurourol Urodyn. 13:1994;1-12.
21. Hachen H.J. Clinical and urodynamic assessment of alpha-adrenolytic therapy in patients with neurogenic bladder dysfunction. Paraplegia. 18:1980;229-238.
22. Yalla S.V., Rossier A.B., Fam B.A., et al. Functional contribution of autonomic innervation to urethral striated sphincter studies with parasympathomimetic, parasympatholytic and alpha-adrenergic blocking agents in spinal cord injury and control male subjects . J Urol. 117:1977;494-499.
23. Jensen D. Altered adrenergic innervation in the uninhibited neurogenic urinary bladder. Scand J Urol Nephrol. Suppl 60:1981;61-62.
24. Petersen T., Husted S.E. Prazosin treatment of neurological patients with lower urinary tract dysfunction. Int Urogynecol J. 4:1993;106-110.
25. Andersson K.E., Ek A., Hedlund H., Mattiasson A. Effects of prazosin on isolated human urethra and in patients with lower motor neuron lesions. Invest Urol. 19:1981;39-42.
26. Jensen D. Uninhibited neurogenic bladder treated with prazosin. Scand J Urol Nephrol. 15:1981;229-233.
27. Petersen T., Husted S.E., Sidenius P. Prazosin treatment of neurological patients with detrusor hyperreflexia and bladder-emptying disability. Scand J Urol Nephrol. 23:1989;189-194.
28. Swierzewski S.J., Gormley E.A., Belville W.D., et al. The effect of terazosin on bladder function in the spinal cord injured patient. J Urol. 151:1994;951-954.
29. Yasuda K., Yamanishi T., Kawabe K., et al. The effect of urapidil on neurogenic bladder a placebo-controlled double-blind study . J Urol. 156:1996;1125-1130.
30. Kaneko S., Minami K., Yachiku S., et al. Bladder neck dysfunction the effect of the alpha-adrenergic blocking agent phentolamine on bladder neck dysfunction and a fluorescent histochemical study of bladder neck smooth muscle . Invest Urol. 18:1980;212-218.
31. Kluck P. The autonomic innervation of the human urinary bladder, bladder neck and urethra a histochemical study . Anat Rec. 198:1980;439-447.
32. Zderic SA, Levin PM, and Wein AJ: Voiding function and dysfunction. Chapter 26A, in Gillenwater GJ, Grayhack JT, and Howards SS, et al (Eds). Adult and Pediatric Urology, 3rd edn. St. Louis, Mosby-Year Book, 1996, pp 1159-1219.
33. Nordling J. Influence of the sympathetic nervous system on lower urinary tract in man. Neurourol Urodyn. 2:1983;3-26.
34. Vodusek D.B., Light J.K. The motor nerve supply of the external urethral sphincter muscles an electrophysiologic study . Neurourol Urodyn. 2:1983;193-200.
35. El Badawi A. Neuromorphologic basis of vesicourethral function. 1. Histochemistry, ultrastructure, and function of intrinsic nerves of the bladder and urethra. Neurourol Urodyn. 1:1982;3.
36. Gosling J. The structure of the bladder and urethra in relation to function. Urol Clin North Am. 6:1979;31-38.
37. Donker PJ, Droes JThPM, and van Ulden BM: Anatomy of the musculature and innervation of the bladder and the urethra, Chapter 50, in Chisholm GD and Williams DI (Eds). Scientific Foundations of Urology. Chicago: Year Book Medical Publishers, 1982, pp 404-411.
38. de Groat W.C. Anatomy and physiology of the lower urinary tract. Urol Clin North Am. 20:1993;383-401.
39. Kunisawa Y., Kawabe K., Niijima T., et al. A pharmacological study of alpha adrenergic receptor subtypes in smooth muscle of human urinary bladder base and prostatic urethra. J Urol. 134:1985;396-398.
40. Kleeman F.J. The physiology of the internal urinary sphincter. J Urol. 104:1970;549-554.
41. Krane R.J., Olsson C.A. Phenoxybenzamine in neurogenic bladder dysfunction. II. Clinical considerations. J Urol. 110:1973;650-653.
42. Vereecken R.L., Van Poppel H., Boeckx G., et al. Long-term alpha-adrenergic blocking therapy in detrusor-urethra dyssynergia Eur Urol. 9:1983;167-169.
43. Nanninga J.B., Kaplan P., Lal S. Effect of phentolamine on perineal muscle EMG activity in paraplegia. Br J Urol. 49:1977;537-539.
44. Nordling J., Meyhoff H., Hald T. Sympatholytic effect on striated urethral sphincter A peripheral or central nervous system effect? Scand J Urol Nephrol. 15:1981;173.
45. Awad S.A., Downie J.W. Sympathetic dyssynergia in the region of the external sphincter a possible source of lower urinary tract obstruction . J Urol. 118:1977;636-640.
46. O'Riordan J.I., Doherty C., Javed M., et al. Do α-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 153:1995;1114-1116.
47. Cramer P., Neveux E., Régnier F., Depassio J., et al. Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, Alfuzosin. Paraplegia. 27:1989;119-124.
48. Perrigot M., Delauche-Cavallier M.C., Amarenco G., Geffriaud C., Stalla-Bourdillon A., Costa P. Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. Neurourol Urodyn. 15:1996;119-131.
49. Abrams P., Griffiths D., Höfner K. The urodynamic assessment of lower urinary tract symptoms. Denis L., Griffiths K., Khoury S., et al. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). 1998;333-347 Health Publications Ltd, Jersey.
50. Scott N.M., Morrow J.W. Phenoxybenzamine in neurogenic bladder dysfunction after spinal cord injury. II. Autonomic dysreflexia. J Urol. 119:1978;483-484.
51. Sizemore G.W., Winternitz W.W. Autonomic hyperreflexia-suppression with alpha-adrenergic blocking agents. N Engl J Med. 282:1970;795.
52. McGuire E.J., Wagner F.M., Weiss R.M. Treatment of autonomic dysreflexia with phenoxybenzamine. J Urol. 115:1976;53-55.
53. Chancellor M.B., Erhard M.J., Hirsch I.H., et al. Prospective evaluation of terazosin for the treatment of autonomic dysreflexia. J Urol. 151:1994;111-113.